Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $86.08, but acceptable to hold if already in. Reasons: Thin upside margin: 3.0%; Below 200-day MA.
Zimmer Biomet designs and markets orthopedic reconstructive implants (knees, hips), sports medicine, biologics, extremities, trauma, CMFT, bone cement, and surgical products globally through Americas, EMEA, and Asia Pacific segments. Approximately 85% of net sales are... Read more
Hold if already holding. Not a fresh buy at $86.08, but acceptable to hold if already in. Reasons: Thin upside margin: 3.0%; Below 200-day MA. Chart setup: Death cross but MACD improving, RSI 69. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Zimmer Biomet Holdings, Inc.
Material events (past 30 days)
- Apr 28, 2026 MEDIUM Item 5.02: CFO Suketu Upadhyay resigned effective April 28, 2026 to pursue a new professional opportunity; no disagreement cited. Paul Stellato (VP/Controller/CAO) appointed as interim CFO. Permanent search underway; Stellato remains principal accounting officer.
Latest news
- Zimmer Biomet (ZBH) Plunges to 13-Year Low on Finance Chief Resignation - Insider Monkey — Insider Monkey negative
- Zimmer Biomet (ZBH) Plunges to 13-Year Low on Finance Chief Resignation - Yahoo Finance — Yahoo Finance negative
- A Look at Zimmer Biomet Holdings Inc (ZBH) After 10.6% Decline -- GF Value $127.12 vs Price $82.80 - GuruFocus — GuruFocus negative
- What is dragging Zimmer (ZBH) stock lower | Q4 2025: EPS Beats Forecasts - Global Trading Community - Xã Thanh Hà — Xã Thanh Hà positive
- ZBH (Zimmer Biomet Holdings Inc.) reports Q4 2025 earnings per share that align perfectly with Wall Street consensus est — Cổng thông tin điện tử tỉnh Tây Ninh positive
Generated 2026-05-20T21:56:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02MEDIUMCFO Suketu Upadhyay resigned effective April 28, 2026 to pursue a new professional opportunity; no disagreement cited. Paul Stellato (VP/Controller/CAO) appointed as interim CFO. Permanent search underway; Stellato remains principal accounting officer.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $86.08, but acceptable to hold if already in. Reasons: Thin upside margin: 3.0%; Below 200-day MA. Chart setup: Death cross but MACD improving, RSI 69. Maintain position. Not compelling to add more. Target $88.67 (+3.0%), stop $81.46 (−5.7%), A.R:R 0.4:1. Score 6.1/10, moderate confidence.
Take-profit target: $88.67 (+3.0% upside). Target $88.67 (+3.0%), stop $81.46 (−5.7%), A.R:R 0.4:1. Stop-loss: $81.46.
Thin upside margin: 3.0%; Below 200-day MA.
Zimmer Biomet Holdings, Inc. trades at a P/E of 22.1 (forward 9.5). TrendMatrix value score: 7.6/10. Verdict: Hold.
35 analysts cover ZBH with a consensus score of 3.3/5. Average price target: $99.
What does Zimmer Biomet Holdings, Inc. do?Zimmer Biomet designs and markets orthopedic reconstructive implants (knees, hips), sports medicine, biologics,...
Zimmer Biomet designs and markets orthopedic reconstructive implants (knees, hips), sports medicine, biologics, extremities, trauma, CMFT, bone cement, and surgical products globally through Americas, EMEA, and Asia Pacific segments. Approximately 85% of net sales are consignment-based; no individual customer exceeded 2% of 2025 net sales.